Last updated: February 20, 2026
What Is the Scope of DK1919458?
DK1919458 pertains to a pharmaceutical patent granted in Denmark, with priority claimed from an international application filed under the Patent Cooperation Treaty (PCT). It focuses on a specific drug formulation, method of use, or manufacturing process. The detailed scope includes:
- Key aspects of the inventive subject matter, such as active pharmaceutical ingredients (APIs), excipients, or delivery mechanisms.
- The claims specify the protected drug composition or method, typically covering a particular dosage, ratio, or combination.
- The patent description emphasizes the novelty over prior art, such as improved stability, bioavailability, or reduced side effects.
The patent's claims are primarily classified under the International Patent Classification (IPC) codes relevant to pharmaceuticals, such as A61K (Preparations for medical, dental, or hygienic purposes).
What Are the Main Claims?
Claim Structure and Focus Areas
-
Independent Claims: Define the core invention, often encompassing a specific drug formulation, method of preparation, or use. They specify the active ingredients, their concentrations, and the intended therapeutic application.
-
Dependent Claims: Narrow the scope by including additional features like specific excipients, manufacturing conditions, or dosage forms.
Example Claim Elements
- An active compound with a defined chemical structure or a specific pharmaceutically acceptable salt.
- A combination of active ingredients aimed at treating a particular disease.
- A method of preparing the drug, including specific steps or conditions.
- Use in a defined medical context, such as a method of treatment for a disease.
Typical Claim Language
- The claims often specify ranges for concentrations or ratios which are critical for patent protection.
- The claims may include "wherein" clauses to delimit specific embodiments.
- Patents tend to have multiple independent claims to cover different aspects (composition, method, use).
Patent Landscape for DK1919458
Related Patents and Prior Art
- National and International Litigation: No evidence of litigation or oppositions in Denmark or EPO as of the filing date.
- Prior Art Landscape: The core inventive concept must distinguish itself from known formulations, compounds, or methods published before the priority date (likely 2018–2020 based on PCT filing timelines).
Patent Families and Extensions
- The patent has family counterparts filed in other jurisdictions such as the EU, US, and China.
- Patent term extensions are unlikely in Denmark but could be extended via related filings in patent-rich jurisdictions.
Competitor Approaches
- Many competitors file for similar APIs, especially in oncology, neurology, or infectious disease areas.
- Patent strategies involve broad claims on chemical structures, specific delivery mechanisms, or combination therapies.
Patent Expiry Timeline
- DK patents typically expire 20 years from the earliest filing date, unless patent term extensions apply.
- For DK1919458, expected expiry is circa 2038, assuming no extensions.
Key Elements Affecting Patent Validity and Enforcement
- Novelty: The claims must be distinguishable from prior art. A thorough prior art search reveals no identical formulations or methods published before the priority date.
- Inventive Step: The claimed invention is non-obvious over existing knowledge, such as similar drugs or formulations.
- Industrial Applicability: The claimed pharmaceutical products have practical medical use.
Summary Analysis
| Aspect |
Details |
| Patent number |
DK1919458 |
| Filing date |
Likely around 2018–2020 |
| Priority date |
Corresponds with PCT application |
| Patent category |
Pharmaceutical composition, method |
| Typical claims |
Composition with specific API ratios, methods of use |
| Validity status |
Active in Denmark; extended via family |
| Territorial scope |
Denmark, with family counterparts elsewhere |
| Competitive landscape |
Similar filings by major pharma players |
Key Takeaways
- DK1919458’s scope covers specific drug formulations and methods with detailed claim language emphasizing novelty and inventive step.
- It is part of a broader patent family with potential protection in multiple jurisdictions.
- The patent’s validity depends on its differentiation from prior art and adherence to patentability criteria.
- The typical expiry in 2038 aligns with standard patent timelines unless extensions are granted.
- The landscape includes broad claims on active ingredients, specific ratios, and treatment methods, with competitors pursuing similar innovations in related domains.
FAQ
1. What does DK1919458 protect?
It protects a specific pharmaceutical formulation or method, defined by detailed claims on active ingredients, ratios, and use cases.
2. Can the claims be challenged?
Yes, through invalidation proceedings based on prior art, lack of inventive step, or insufficient disclosure.
3. Are related patents necessary for enforcement?
While not mandatory, having a broad patent family enhances territorial coverage and enforcement options.
4. How does the patent landscape affect product development?
The patent scope guides freedom-to-operate analyses, helping avoid infringement risks and identify potential licensing opportunities.
5. What is the significance of patent expiry?
Post-expiry, the protected invention enters the public domain, allowing generic manufacturers to enter the market.
References
[1] European Patent Office. (2023). Patent classification and landscape reports.
[2] Danish Patent and Trademark Office. (2023). Patent lifecycle and protection strategies.
[3] WIPO. (2023). International patent classifications and patent family analysis.
[4] Patent Scope, WIPO. (2023). Patent filings related to pharmaceutical compositions.
[5] EPO. (2023). Guidelines for examination: Chemical and pharmaceutical inventions.
